Introduction
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin characterized by recurrent nodules, abscesses, sinus tract formation and scarring affecting mainly areas rich with apocrine glands including the axillae, groin, buttocks, perianal and submammary regions. The disease initially presents during puberty and is more common in females. Treatment options include oral antibiotics, isotretinoin, finasteride, prednisone, cyclosporine, surgery, carbon dioxide laser therapy and radiotherapy. Recently, the efficacy of different biologics has been demonstrated. We report a patients with long-standing active hidradenitis suppurativa who was successfully treated with adalimumab.
The case
A 25-year-old arabic female presented with a 14-year history of painful discharging nodules, sinuses and cysts involving axillae (Fig. 1, a) , submammary region and groin. Her past medical history was negative except for mild acne vulgaris affecting the face. There was no history of inflammatory bowel disease or any other medical illnesses. Physical examination of the axillary areas, submammary and the groins revealed multiple erythematous tender nodules with discharging sinuses and abcesses. Some areas were macerated due to the contineous severe inflammation. Other areas showed healed hypertrophic scars. Her baseline investigations including complete blood count, liver function tests, renal function tests, lipid profile, anitnuclear antibodies, antidouble stranded DNA, complement 3 and 4 and c reactive protiens were within normal limits. Culture of the discharge from the abcesses was negative. So the patient was diagnosed as a case of HS. Initially, she was treated with oral isotretinoin 1 mg per kg for 5 months with no improvement then a course of oral doxycycline 100 mg once daily for 12 weeks failed to improve the condition. A single course of Infliximab (three intravenous infusions at weeks 0, 2 and 6) was started for 10 weeks with minimal improvement. Over a period of few months the condition worsened so she was admitted to the surgical ward for wound care and debridement. After a period of one month the patient was started on Adalimumab 80 mg subcutaneous as a loading dose followed by 40 mg every one week for 16 weeks. The condition improved immediately with regard to the lesions size and the discharge with no new lesions appearing. She maintained her response for almost one year but due to unavailability of adalimumab in the hospital the patient discontinued taking it for three months. This time, she presented to the clinic with severe relapse. Adalimumab was restarted with a dose of 160 mg subcutaneous injection as a loading dose followed by 80 mg in the following week then mainatianed on 40 mg weekly with an excellent response (Fig. 1, b) . She is being followed up every 8 weeks in the clinic with good control of the lesions.
Discussion
Hidradenitis suppurativa (HS) was first described in 1839 by Velpeau [1] . It was classified as a member of the follicular occlusion triad, along with Acne conglobata and dissecting cellulitis of the scalp [2, 3] . In 1975, pilonidal cyst was added as a member to this triad, forming the follicular occlusion tetrad [4] . The global HS prevalence was reported as 1 % in a review of several studies with female predominance [5] [6] [7] . The mode of inheritance of HS remains unclear. Genetic studies have indicated several gene loci on chromosomes 6q25.1-25.2 and 9p12-p13.11 but no causative genes have yet been identified [8] . The disease is essentially limited to areas of the skin that are rich in terminal hair follicles and apocrine glands, such as the axillae, anogenital area, submammary areas and the buttocks [7, 9] . Clinically, it is characterized by recurring pustules, inflammatory nodules, abscesses, draining sinus formation, fibrosis, secondary lymphedema and double-ended pseudocomedones. In its severe form it can be a devastating disease with a great impact on the quality of life [10] . HS transformation into SCC has been documented in 41 reports [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 
Conclusions
This is a case of chronic persistent HS that failed all classical therapies for HS but has shown superior response with adalimumab. Hopefully, future reports will reveal the pathogenesis of HS through the action of these drugs which might lead to discovery of specific new innovative therapies to this debilitating condition. 
